Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid + AH2 + O2
? + A + H2O
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid + AH2 + O2
? + A + H2O
substrate binding structure and nonproductive conformation, overview
-
-
?
8,11,14-eicosatrienoic acid + O2
prostaglandin G1 + ?
8,11,14-eicosatrienoic acid + O2
prostaglandin H1 + ?
alpha-linolenic acid + reduced acceptor + O2
?
arachidonate + 2 O2
prostaglandin G2
-
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin G2 + A + ?
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
arachidonate + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin G2 + oxidized N,N,N',N'-tetramethylphenylenediamine + ?
-
-
-
?
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin H2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
arachidonic acid + 2 O2
prostaglandin G2
cyclooxygenase reaction, arachidonic acid as electron donor
-
-
?
arachidonic acid + 3,4-methylenedioxyamphetamine
?
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
arachidonic acid + 3,4-methylenedioxymethamphetamine
?
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
arachidonic acid + AH2 + 2 O2
15(R)-hydroxy-eicosatetraenoic acid + A + H2O
arachidonic acid + AH2 + 2 O2
15-hydroperoxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid + A + H2O
-
-
-
?
arachidonic acid + AH2 + 2 O2
6-keto-prostaglandin F1alpha + A + H2O
-
activity assay
-
-
?
arachidonic acid + AH2 + 2 O2
prostaglandin E2 + A + H2O
arachidonic acid + methamphetamine
?
-
postulated bioactivation to a neurodegenerative free radical intermediate that can initiate the formation of reactive oxygen species
-
-
?
arachidonic acid + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
-
-
-
-
r
cis-11,14-eicosadienoic acid + AH2 + O2
?
-
-
-
?
cis-11,14-eicosadienoic acid + reduced acceptor + O2
?
-
-
-
-
r
cis-4,7,10,13,16,19-docosahexaenoic acid + AH2 + O2
?
-
-
-
?
cis-5,8,11,14,17-eicosapentaenoic acid + AH2 + O2
?
-
-
-
?
cis-5,8,11,14,17-eicosapentaenoic acid + reduced acceptor + O2
?
cis-5,8,11,14-eicosatetraenoic acid + AH2 + O2
?
-
-
-
?
cis-7,10,13,16-docosatetraenoic acid + AH2 + O2
?
-
-
-
?
cis-7,10,13,16-docosatetraenoic acid + reduced acceptor + O2
?
cis-8,11,14-eicosatrienoic acid + AH2 + O2
?
-
-
-
?
cis-8,11,14-eicosatrienoic acid + reduced acceptor + O2
?
gamma-linolenic acid + AH2 + O2
?
-
-
-
?
gamma-linolenic acid + reduced acceptor + O2
?
guaiacol + trans-5-phenyl-4-pentenyl-1-hydroperoxide
?
-
-
-
-
?
H2O2 + guaiacol
?
-
peroxidase activity
-
-
?
H2O2 + N,N,N',N'-tetramethyl-p-phenylenediamine
?
-
peroxidase activity
-
-
?
linoleic acid + AH2 + O2
9-hydroxyoctadecadienoic acid + 13-hydroxyoctadecadienoic acid + ?
linolenic acid + AH2 + O2
?
-
-
-
?
prostaglandin G2 + AH2
prostaglandin H2 + A + H2O
-
-
-
-
?
additional information
?
-
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid + AH2 + O2
? + A + H2O
the substrate is bound in the cyclooxygenase channel of COX-2, binding structure, overview. The carboxylate of docosahexaenoate interacts with Arg120 and Tyr355 at the base of the channel and the omega-end abuts the side chain of Ile377 near Gly533 in the hydrophobic groove above Ser530
-
-
?
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid + AH2 + O2
? + A + H2O
-
-
-
-
?
(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid + AH2 + O2
? + A + H2O
-
-
-
?
8,11,14-eicosatrienoic acid + O2
prostaglandin G1 + ?
-
-
-
?
8,11,14-eicosatrienoic acid + O2
prostaglandin G1 + ?
-
bis-dioxygenase activity, cyclooxygenase activity, presence of hematin
9alpha,11alpha-epidioxy-15(S)-hydroperoxy-13-trans-prostenoic acid
?
8,11,14-eicosatrienoic acid + O2
prostaglandin H1 + ?
-
-
-
-
?
8,11,14-eicosatrienoic acid + O2
prostaglandin H1 + ?
-
hydroperoxidase activity, presence of hematin and tryptophan
-
-
?
alpha-linolenic acid + reduced acceptor + O2
?
-
-
-
-
r
alpha-linolenic acid + reduced acceptor + O2
?
-
-
-
r
arachidonate + AH2 + 2 O2
prostaglandin G2 + A + ?
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin G2 + A + ?
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + 2 O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
the reaction comprises two steps: dioxygenation of arachidonate to yield prostaglandin G2 containing both a 9-11 endoperoxide and a 15-peroxide group, and a peroxidase reaction, which converts prostaglandin G2 to prostaglandin H2 where the 15-peroxide is reduced to an alcohol
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
substrate binding structure and nonproductive conformation, overview
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
the reaction comprises two steps: dioxygenation of arachidonate to yield prostaglandin G2 containing both a 9-11 endoperoxide and a 15-peroxide group, and a peroxidase reaction, which converts prostaglandin G2 to prostaglandin H2 where the 15-peroxide is reduced to an alcohol
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
?
arachidonate + AH2 + O2
prostaglandin H2 + A + H2O
-
-
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
-
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
-
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
cyclooxygenase activity
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
-
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
-
-
-
?
arachidonate + electron donor + O2
prostaglandin H2 + oxidized electron donor + H2O
-
-
-
-
?
arachidonate + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
-
-
-
-
?
arachidonate + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
-
-
-
-
?
arachidonate + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
-
-
-
?
arachidonate + reduced acceptor + O2
prostaglandin H2 + acceptor + H2O
-
-
-
?
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin H2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
-
-
-
?
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin H2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
-
-
-
?
arachidonate + reduced N,N,N',N'-tetramethylphenylenediamine + 2 O2
prostaglandin H2 + oxidized N,N,N',N'-tetramethylphenylenediamine + H2O
-
-
-
?
arachidonic acid + AH2 + 2 O2
15(R)-hydroxy-eicosatetraenoic acid + A + H2O
-
-
product of aspirin acetylated enzyme or S516M mutant
?
arachidonic acid + AH2 + 2 O2
15(R)-hydroxy-eicosatetraenoic acid + A + H2O
-
-
product of aspirin treated enzyme
?
arachidonic acid + AH2 + 2 O2
prostaglandin E2 + A + H2O
-
-
-
?
arachidonic acid + AH2 + 2 O2
prostaglandin E2 + A + H2O
-
-
-
?
arachidonic acid + AH2 + 2 O2
prostaglandin E2 + A + H2O
-
-
-
?
cis-5,8,11,14,17-eicosapentaenoic acid + reduced acceptor + O2
?
-
-
-
-
r
cis-5,8,11,14,17-eicosapentaenoic acid + reduced acceptor + O2
?
-
-
-
r
cis-7,10,13,16-docosatetraenoic acid + reduced acceptor + O2
?
-
-
-
-
r
cis-7,10,13,16-docosatetraenoic acid + reduced acceptor + O2
?
-
-
-
r
cis-8,11,14-eicosatrienoic acid + reduced acceptor + O2
?
-
-
-
-
r
cis-8,11,14-eicosatrienoic acid + reduced acceptor + O2
?
-
-
-
r
gamma-linolenic acid + reduced acceptor + O2
?
-
-
-
-
r
gamma-linolenic acid + reduced acceptor + O2
?
-
-
-
r
linoleic acid + AH2 + O2
9-hydroxyoctadecadienoic acid + 13-hydroxyoctadecadienoic acid + ?
-
-
-
?
linoleic acid + AH2 + O2
9-hydroxyoctadecadienoic acid + 13-hydroxyoctadecadienoic acid + ?
-
-
-
?
additional information
?
-
-
major products of arachidonic acids are prostaglandins D2 and E2, minor products prostaglandin F2alpha and 6-keto-prostaglandin F1alpha
-
-
?
additional information
?
-
-
dopamine precursor L-dihydroxyphenylalanine, i.e. L-DOPA, and metabolites dihydroxyphenylacetic acid, homovanillic acid, and 3-methoxytyramine may serve as substrates for prostaglandin H synthase-catalyzed bioactivation to free radical intermediates
-
-
?
additional information
?
-
-
PGHS-2 also shows cyclooxygenase activity
-
-
?
additional information
?
-
activity with arachidonate in presence of glutathione leads to formation of malondialdehyde and (15S)-8-iso-prostaglandin F2alpha
-
-
?
additional information
?
-
activity with arachidonate in presence of glutathione leads to formation of malondialdehyde and (15S)-8-iso-prostaglandin F2alpha
-
-
?
additional information
?
-
PGHS-1 also exhibits peroxidase activity
-
-
?
additional information
?
-
PGHS-1 also exhibits peroxidase activity
-
-
?
additional information
?
-
-
PGHS-1 also exhibits peroxidase activity
-
-
?
additional information
?
-
PGHS-2 also exhibits peroxidase activity
-
-
?
additional information
?
-
PGHS-2 also exhibits peroxidase activity
-
-
?
additional information
?
-
-
PGHS-2 also exhibits peroxidase activity
-
-
?
additional information
?
-
-
relative activities of isozymes 1,2 depend on source of arachidonic acid - exogenous versus endogenous
-
-
?
additional information
?
-
although arachidonic acid is the preferred substrate, other fatty acids are oxygenated by the isozymes with varying efficiencies. The substrates bind in different conformations in each monomer constituting the homodimer in their respective structures such that one monomer exhibits nonproductive binding and the other productive binding of the substrate in the cyclooxygenase channel, Arg120 and Leu531 play a role, overview
-
-
?
additional information
?
-
-
although arachidonic acid is the preferred substrate, other fatty acids are oxygenated by the isozymes with varying efficiencies. The substrates bind in different conformations in each monomer constituting the homodimer in their respective structures such that one monomer exhibits nonproductive binding and the other productive binding of the substrate in the cyclooxygenase channel, Arg120 and Leu531 play a role, overview
-
-
?
additional information
?
-
-
electron donors used by hydroperoxidase: phenylbutazone, sulindac
-
-
?
additional information
?
-
-
formation of prostaglandin E2, prostaglandin F2alpha and prostaglandin D2 from arachidonic acid
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
electron donors used by hydroperoxidase: phenylbutazone, sulindac
-
-
?
additional information
?
-
-
electron donors used by hydroperoxidase: phenylbutazone, sulindac
-
-
?
additional information
?
-
-
xenobiotics such as benzo(a)pyrene cannot act as electron donor, but undergo cooxydation during hydroperoxidase reaction
-
-
?
additional information
?
-
-
functional differentiation of cyclooxygenase and peroxidase activities by trypsin treatment
-
-
?
additional information
?
-
-
cooxidation of: 4-chloroaniline to yield N-(4-chlorophenyl)-hydroxylamine and 1-chloro-4-nitrosobenzene
-
-
?
additional information
?
-
-
also catalyzed: transformation of arachidonic acid into prostaglandin E2, prostaglandin F2 alpha and 12-hydroxy-5,8,10-heptadecatrienoic acid
-
-
?
additional information
?
-
-
first step in prostaglandin synthesis
-
-
?
additional information
?
-
-
first step in prostaglandin synthesis
-
-
?
additional information
?
-
-
enzyme has a central position in prostanoic metabolism: first step in formation of prostaglandins and thromboxanes, the conversion of arachidonic acid to prostaglandin endoperoxides G and H
-
-
?
additional information
?
-
prostaglandin synthesis within the fetal central nervous system is critical for the the modulation of hypotension-induced fetal ACTH secretion involving PGHS-2, overview
-
-
?
additional information
?
-
prostaglandin synthesis within the fetal central nervous system is critical for the the modulation of hypotension-induced fetal ACTH secretion involving PGHS-2, overview
-
-
?
additional information
?
-
-
prostaglandin synthesis within the fetal central nervous system is critical for the the modulation of hypotension-induced fetal ACTH secretion involving PGHS-2, overview
-
-
?
additional information
?
-
-
maximal values of the initial reaction rate and yield of the product are attained at oxygen concentration 0.05 mM
-
-
?
additional information
?
-
-
the expression of PGHS-2 may be involved in inhibiting progesterone production
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1,10-phenanthroline
-
weak
1-Mercapto-9,11,15-trihydroxyprosta-5,13-diene
-
inhibition of prostaglandin G1 synthesis
1-Mercapto-9-oxo-11,15-dihydroxyprosta-5,13-dione
-
inhibition of prostaglandin G1 synthesis
12-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
14-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
15-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
2,3-Dimercaptopropanol
-
inhibition of prostaglandin G1 synthesis
2-hydroxybutyric acid
-
weak
3,6-bis(3-[[(furan-2-yl)methyl]amino]propyl)-9H-xanthen-9-one
-
3,6-bis(5-[[(furan-2-yl)methyl]amino]pentyl)-9H-xanthen-9-one
-
3,6-bis[3-(2-methyl-1H-indol-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(4-methylpiperazin-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(4-nitroanilino)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(cyclohexylamino)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(morpholin-4-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(piperidin-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(1H-pyrazol-3-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(2-chloropyridin-3-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(4H-1,2,4-triazol-4-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(pyrazin-2-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(pyridin-2-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[4-(1H-imidazol-2-yl)butyl]-9H-xanthen-9-one
-
3,6-bis[5-(2-methyl-1H-indol-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(4-methylpiperazin-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(4-nitroanilino)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(cyclohexylamino)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(morpholin-4-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(piperidin-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(1H-pyrazol-3-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(2-chloropyridin-3-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(4H-1,2,4-triazol-4-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(piperidin-1-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(pyrazin-2-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(pyridin-2-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[6-(1H-imidazol-2-yl)hexyl]-9H-xanthen-9-one
-
5,8,11,14-Eicosatetraynoic acid
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
6-methoxy-2-naphthyl acetic acid
-
active metabolite of nabumetone, isozyme 1, 50% inhibition at 0.2-0.8 mM, isozyme 2, 50% inhibition at 0.015-0.55 mM
6-methylnaphthylacetic acid
-
recombinant protein, 50% inhibition at 0.08-0.1 mM
6-[2,4-difluorophenoxy]-5-methyl-sulfonylamino-1-indanone
-
CGP28238, an isozyme-2 specific inhibitor, 65% inhibition at 100 nM
9,11-Dihydroxy-15S-mercaptoprosta-5,13-dienoic acid
-
or 15R-isomer, inhibition of prostaglandin G1 synthesis
9-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase activity and peroxidase activity of PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
anirolac
-
isozyme 1, 50% inhibition at 0.0007 mM, isozyme 2, 50% inhibition at 0.009 mM
bicarbonate
-
bicarbonate enhances peroxynitrite-mediated peroxidase inactivation
BW 755C
-
recombinant protein, 50% inhibition at 0.01-0.02 mM
DCM-extract of Angelicae dahuricae radix
0.1% inhibition of PGHS-1; 38.8% inhibition of PGHS-2
-
DCM-extract of Angelicae sinsesis radix
55.8% inhibition of PGHS-2; 75.0% inhibition of PGHS-1
-
DCM-extract of Atractylodis lanceae rhizoma
46.9% inhibition of PGHS-1; 50.3% inhibition of PGHS-2
-
DCM-extract of Atractylodis macrocephalae rhizoma
47.0% inhibition of PGHS-2; 58.6% inhibition of PGHS-1
-
DCM-extract of Cinnamomi ramulus
48.4% inhibition of PGHS-2; 73.5% inhibition of PGHS-1
-
DCM-extract of Houttuyniae herba
40.9% inhibition of PGHS-2; 46.8% inhibition of PGHS-1
-
DCM-extract of Notopterygii rhizoma seu radix
-2.1% inhibition of PGHS-2; 42.6% inhibition of PGHS-1
-
DCM-extract of Piperis sarmentosi herba
10.1% inhibition of PGHS-2; 47.2% inhibition of PGHS-1
-
DCM-extract of Platycodi radix
70.1% inhibition of PGHS-2; 77.8% inhibition of PGHS-1
-
DCM-extract of Zanthoxyli pericarpium
18.3% inhibition of PGHS-1; 31.3% inhibition of PGHS-2
-
DCM-extract of Zingiberis rhizoma
41.3% inhibition of PGHS-2; 52.9% inhibition of PGHS-1
-
delta-tocopherol-13'-carboxychromanol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
-
delta-tocotrienol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
delta-tocotrienol-13'-carboxychromanol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
-
diethyldithiocarbamate
-
-
dihydrolipoic acid
-
inhibition of prostaglandin G1 synthesis
dithiothreitol
-
inhibition of prostaglandin G1 synthesis
docosahexaenoic acid
-
isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.015 mM
Eicosa-5,8,11,14-tetraynoic acid
-
-
ellagic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
etodalac
-
recombinant protein, 50% inhibition at 0.06-0.07 mM
ETYA
-
recombinant protein, 50% inhibition at 0.015-0.025 mM
fatty acid
-
of low molecular mass
fenclofenac
-
isozyme 1, 50% inhibition at 0.007 mM, isozyme 2, 50% inhibition at 0.004 mM
flosulide
-
selective for isozyme 2, 50% inhibition at 130 nM
Flufenamic acid
-
50% inhibition at 0.02 mM
L-745
-
isozyme 1, 50% inhibition at 0.369 mM, isozyme 2, 50% inhibition at 0.002 mM
Mefenamic acid
-
isozyme 1, 50% inhibition at 0.01 mM, isozyme 2, 50% inhibition at 0.0003 mM
meloxicam
-
isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.0004 mM
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
n-hexane extract of Angelicae dahuricae radix
42.4% inhibition of PGHS-2; 52.5% inhibition of PGHS-1
-
n-hexane extract of Angelicae sinsesis radix
61.5% inhibition of PGHS-2; 73.0% inhibition of PGHS-1
-
n-hexane extract of Atractylodis lanceae rhizoma
67.4% inhibition of PGHS-1; 68.3% inhibition of PGHS-2
-
n-hexane extract of Atractylodis macrocephalae rhizoma
46.1% inhibition of PGHS-1; 48.9% inhibition of PGHS-2
-
n-hexane extract of Cinnamomi ramulus
23.6% inhibition of PGHS-2; 46.6% inhibition of PGHS-1
-
n-hexane extract of Houttuyniae herba
43.4% inhibition of PGHS-2; 50.3% inhibition of PGHS-1
-
n-hexane extract of Notopterygii rhizoma seu radix
64.9% inhibition of PGHS-2; 69.6% inhibition of PGHS-1
-
n-hexane extract of Piperis sarmentosi herba
52.4% inhibition of PGHS-1; 65.0% inhibition of PGHS-2
-
n-hexane extract of Platycodi radix
48.7% inhibition of PGHS-1; 55.1% inhibition of PGHS-2
-
n-hexane extract of Zanthoxyli pericarpium
24.9% inhibition of PGHS-2; 48.5% inhibition of PGHS-1
-
n-hexane extract of Zingiberis rhizoma
77.5% inhibition of PGHS-2; 83.4% inhibition of PGHS-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
niflumic acid
-
isozyme 1, 50% inhibition at 0.016 mM, isozyme 2, 50% inhibition at 0.0001 mM
Non-steroidal anti-inflammatory agents
-
O2
-
the cyclooxygenase reaction is inhibited by an excess of dissolved oxygen, 0.5 mM O2 causes twofold decrease in the initial rate and maximal yield
PD-98059
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
SB203580
inhibitor of p38, reduces the PGHS-2 response to oxygen and glucose depivation by approximately 50%
SC58125
-
isozyme 1, 50% inhibition at 0.039 mM, isozyme 2, 50% inhibition at 0.0003 mM
sulindac sulfide
-
isozyme 1, 50% inhibition at 0.0004 mM, isozyme 2, 50% inhibition at 0.012 mM
suprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.002mM
Tannic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
U0126
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
5,8,11,14-Eicosatetraynoic acid
-
-
5,8,11,14-Eicosatetraynoic acid
complete inhibition at 0.04 mM
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 7.6fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 7.6fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
-
DuP-697, selective for isozyme 2
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
-
50% inhibition at 8.7 nM
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 29.7fold selectivity for isoform Cox-2 over Cox-1
-
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 29.7fold selectivity for isoform Cox-2 over Cox-1
-
Acetylsalicylic acid
-
inhibition of prostaglandin G1 synthesis
Acetylsalicylic acid
-
an irreversible inhibitor of both hPHS-1 and hPHS-2
Acetylsalicylic acid
-
isozyme 1, complete inhibition, isozyme 2, change in reaction, main product from arachidonate is 15-hydroxyeicosatetraenoic acid
Acetylsalicylic acid
-
irreversible inhibitor
Acetylsalicylic acid
-
inhibition of oxygenase activity by acetylating a serine residue of the enzyme
albumin
-
-
-
albumin
-
bovine serum albumin inhibits by binding of arachidonic acid
-
aspirin
-
-
aspirin
-
cyclooxygenase activity
diclofenac
-
recombinant protein, 50% inhibition at 0.04 mM
diclofenac
-
50% inhibition at 9.4 nM
diclofenac
-
isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0015 mM
diclofenac
-
isozyme 1, 50% inhibition at 0.0003 mM, isozyme 2, 50% inhibition at 18 nM
DUP-697
-
a standard PHS-2 inhibitor
DUP-697
-
a PHS-2-specific inhibitor
flurbiprofen
-
isozyme 1, 50% inhibition at 40 nM, isozyme 2, 50% inhibition at 500 nM
flurbiprofen
-
isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0009 mM
flurbiprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.003 mM
flurbiprofen
-
cyclooxygenase inhibitor
Ibuprofen
-
recombinant protein, 50% inhibition at 0.04 mM
Ibuprofen
-
50% inhibition at 0.253 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.0026 mM, isozyme 2, 50% inhibition at 0.0015 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.018 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.09 mM, isozyme 2, 50% inhibition at 0.008 mM
indomethacin
-
inhibition of prostaglandin G1 synthesis
indomethacin
-
acts on isozyme 1 and 2, 85% inhibition at 100 nM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
reversible and time-dependent inhibition
indomethacin
-
50% inhibition at 100 nM
indomethacin
-
isozyme 1, 50% inhibition at 0.0017 mM, isozyme 2, 50% inhibition at 0.025 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
isozyme 1 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0003 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.130-0.160 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
inhibition in gastrointestinal tissues
Ketoprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0025 mM
Ketoprofen
-
isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.018 mM
Meclofenamic acid
-
isozyme 1, 50% inhibition at 0.002 mM, isozyme 2, 50% inhibition at 0.015 mM
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 135fold selectivity for isoform Cox-2 over Cox-1
-
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 135fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 120fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 120fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 114fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 114fold selectivity for isoform Cox-2 over Cox-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 145fold selectivity for isoform Cox-2 over Cox-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 145fold selectivity for isoform Cox-2 over Cox-1
-
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
NS-398, selective for isozyme 2
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
50% inhibition at 81 nM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
isozyme 1, 50% inhibition at 0.017 mM, isozyme 2, 50% inhibition at 0.0001 mM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
naproxen
-
recombinant protein, 50% inhibition at 0.05-0.06 mM
naproxen
-
isozyme 1, 50% inhibition at 0.0006 mM, isozyme 2, 50% inhibition at 0.002 mM
naproxen
inhibitor of cyclooxigenase reaction; inhibitor of cyclooxigenase reaction
nimesulide
-
isozyme 1, 50% inhibition at 0.07 mM, isozyme 2, 50% inhibition at 0.0013 mM
nimesulide
-
isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.0005 mM
nimesulide
-
inhibits the cyclooxygenase activity, a COX-2-specific inhibitor
Non-steroidal anti-inflammatory agents
-
inhibition of cyclooxygenase activity
-
Non-steroidal anti-inflammatory agents
-
inhibition of cyclooxygenase activity
-
NS-398
inhibits PTGS2
piroxicam
-
isozyme 1, 50% inhibition at 0.009-0.024 mM, isozyme 2, 50% inhibition at 0.070-0.240 mM
piroxicam
-
isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM
quercetin
-
quercetin 3-O-glucoside
-
quercetin 3-O-glucoside
-
SC-560
-
a standard PHS-1 inhibitor
SC-560
-
a PHS-1-specific inhibitor
additional information
algal PGHS is not inhibited by non-steroidal anti-inflammatory drugs that inhibit the mammalian enzymes
-
additional information
-
algal PGHS is not inhibited by non-steroidal anti-inflammatory drugs that inhibit the mammalian enzymes
-
additional information
-
effect of cofactor, enzyme and substrate concentration on inhibition by human serum, haptoglobin and albumin
-
additional information
-
mechanism of selective inhibition
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
-
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
-
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
-
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0368
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
pH 8.0, 25°C, COX-2 mutant N580A
0.00945
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
pH 8.0, 25°C, COX-2 mutant N580A
0.0031 - 0.082
alpha-linolenic acid
0.0009 - 0.015
arachidonate
0.001 - 0.16
arachidonic acid
0.0052 - 0.0091
cis-11,14-eicosadienoic acid
0.0011 - 0.07
cis-4,7,10,13,16,19-docosahexaenoic acid
0.0012 - 0.039
cis-5,8,11,14,17-eicosapentaenoic acid
0.0017 - 0.013
cis-5,8,11,14-eicosatetraenoic acid
0.0027 - 0.061
cis-7,10,13,16-docosatetraenoic acid
0.002 - 0.036
cis-8,11,14-eicosatrienoic acid
0.0048 - 0.162
gamma-linolenic acid
0.0055 - 0.0068
linoleic acid
0.0083 - 0.0854
N,N,N',N'-tetramethyl-p-phenylenediamine
0.02 - 0.437
trans-5-phenyl-4-pentenyl-1-hydroperoxide
additional information
additional information
-
0.0031
alpha-linolenic acid
-
0.0048
alpha-linolenic acid
-
-
0.0101
alpha-linolenic acid
-
0.082
alpha-linolenic acid
-
0.0009
arachidonate
purified isoform PGHS-2, method: coupled, homo-vanilic acid
0.0011
arachidonate
purified isoform PGHS-2, method: direct, O2
0.0017
arachidonate
purified isoform PGHS-2, method: direct, O2
0.0019
arachidonate
purified isoform PGHS-1, method: direct, O2
0.002
arachidonate
purified isoform PGHS-2, method: direct, O2
0.0021
arachidonate
-
native enzyme
0.0021
arachidonate
-
pH 7.2, 30°C, mutant enzyme N382L
0.0021
arachidonate
-
pH 7.2, 30°C, PGHS-2 wild-type enzyme
0.0022
arachidonate
-
pH 7.2, 30°C, mutant enzyme N383D
0.0027
arachidonate
purified isoform PGHS-1, method: coupled, homo-vanilic acid
0.0029
arachidonate
-
pH 7.2, 30°C, mutant enzyme N382D
0.00295
arachidonate
pH 8.0, 25°C, COX-2 mutant L531P
0.003
arachidonate
purified isoform PGHS-1, method: direct, O2
0.0032
arachidonate
-
mutant enzyme Y148F
0.0036
arachidonate
-
mutant enzyme Y404F
0.00365
arachidonate
pH 8.0, 25°C, COX-2 mutant L531A
0.0037
arachidonate
-
pH 7.2, 30°C, mutant enzyme N383H
0.0037
arachidonate
purified isoform PGHS-1, method: direct, O2
0.0038
arachidonate
-
mutant enzyme Y348F
0.0041
arachidonate
-
pH 7.2, 30°C, mutant enzyme N382A
0.0042
arachidonate
-
mutant enzyme Y504F
0.0043
arachidonate
-
mutant enzyme Y148F/Y348F/Y404F/Y504F
0.0045
arachidonate
purified isoform PGHS-1, method: direct, O2
0.005
arachidonate
purified isoform PGHS-2, method: direct, O2
0.0051
arachidonate
purified isoform PGHS-2, method: direct, O2
0.00514
arachidonate
pH 8.0, 25°C, COX-2 wild-type COX-2 and mutant N580A
0.009
arachidonate
purified isoform PGHS-2, method: direct, O2
0.0092
arachidonate
purified isoform PGHS-2, method: direct, O2
0.01
arachidonate
purified isoform PGHS-2, method: direct, arachidonate
0.01
arachidonate
purified isoform PGHS-2, method: direct, trimethyl phosphine oxide
0.0102
arachidonate
purified isoform PGHS-1, method: direct, arachidonate
0.011
arachidonate
purified isoform PGHS-1, method: coupled, homo-vanilic acid
0.015
arachidonate
purified isoform PGHS-1, method: direct, O2
0.001
arachidonic acid
-
isozyme 1 and 2
0.0021
arachidonic acid
-
wild-type, cyclooxygenase activity
0.0034
arachidonic acid
-
mutant Y348F/Y504F, cyclooxygenase activity
0.0038
arachidonic acid
-
mutant Y348F, cyclooxygenase activity
0.0042
arachidonic acid
-
mutant Y504F, cyclooxygenase activity
0.0045
arachidonic acid
-
isozyme 1
0.005
arachidonic acid
-
isozyme 2
0.006
arachidonic acid
-
-
0.0083
arachidonic acid
-
-
0.015
arachidonic acid
-
-
0.16
arachidonic acid
-
-
0.0052
cis-11,14-eicosadienoic acid
-
0.0091
cis-11,14-eicosadienoic acid
-
-
0.0011
cis-4,7,10,13,16,19-docosahexaenoic acid
-
0.0033
cis-4,7,10,13,16,19-docosahexaenoic acid
-
-
0.0318
cis-4,7,10,13,16,19-docosahexaenoic acid
-
0.07
cis-4,7,10,13,16,19-docosahexaenoic acid
-
0.0012
cis-5,8,11,14,17-eicosapentaenoic acid
-
0.0031
cis-5,8,11,14,17-eicosapentaenoic acid
-
-
0.0153
cis-5,8,11,14,17-eicosapentaenoic acid
-
0.039
cis-5,8,11,14,17-eicosapentaenoic acid
-
0.0017
cis-5,8,11,14-eicosatetraenoic acid
-
0.0024
cis-5,8,11,14-eicosatetraenoic acid
-
0.003
cis-5,8,11,14-eicosatetraenoic acid
-
-
0.013
cis-5,8,11,14-eicosatetraenoic acid
-
0.0027
cis-7,10,13,16-docosatetraenoic acid
-
0.007
cis-7,10,13,16-docosatetraenoic acid
-
-
0.0357
cis-7,10,13,16-docosatetraenoic acid
-
0.061
cis-7,10,13,16-docosatetraenoic acid
-
0.002
cis-8,11,14-eicosatrienoic acid
-
0.0055
cis-8,11,14-eicosatrienoic acid
-
-
0.0059
cis-8,11,14-eicosatrienoic acid
-
0.036
cis-8,11,14-eicosatrienoic acid
-
0.0048
gamma-linolenic acid
-
0.0071
gamma-linolenic acid
-
-
0.162
gamma-linolenic acid
-
0.08
guaiacol
-
pH 8.0, 23°C, wild-type enzyme
0.29
guaiacol
-
pH 8.0, 23°C, mutant enzyme N382L
1.3
H2O2
-
pH 8.0, 23°C, wild-type enzyme
5.5
H2O2
-
pH 8.0, 23°C, mutant enzyme N382L
0.0055
linoleic acid
isozyme PGHS-1, in 100 mM Tris-HCl buffer (pH 7.4), at 24°C
0.0068
linoleic acid
isozyme PGHS-2, in 100 mM Tris-HCl buffer (pH 7.4), at 24°C
0.0083
N,N,N',N'-tetramethyl-p-phenylenediamine
-
pH 7.2, 30°C, mutant enzyme N383H
0.01
N,N,N',N'-tetramethyl-p-phenylenediamine
-
pH 7.2, 30°C, mutant enzyme N383D
0.0156
N,N,N',N'-tetramethyl-p-phenylenediamine
-
pH 7.2, 30°C, mutant enzyme N382D
0.0163
N,N,N',N'-tetramethyl-p-phenylenediamine
-
pH 7.2, 30°C, PGHS-2 wild-type enzyme
0.0854
N,N,N',N'-tetramethyl-p-phenylenediamine
-
pH 7.2, 30°C, mutant enzyme N382L
0.005
O2
purified isoform PGHS-1, method: direct, O2
0.0055
O2
purified isoform PGHS-1, method: direct, O2
0.01
O2
purified isoform PGHS-1, method: direct, arachidonate
0.011
O2
purified isoform PGHS-1, method: direct, O2
0.02
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y148F
0.061
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y404F
0.072
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y348F
0.103
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y148F/Y348F/Y385F/Y404F/Y504F
0.138
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
native enzyme
0.339
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y385F
0.37
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y148F/Y348F/Y404F/Y504F
0.437
trans-5-phenyl-4-pentenyl-1-hydroperoxide
-
mutant enzyme Y504F
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
-
Michaelis-Menten kinetics
-
additional information
additional information
Michaelis-Menten kinetics, overview
-
additional information
additional information
-
Michaelis-Menten kinetics, overview
-
additional information
additional information
-
the cyclooxygenase reaction shows Michaelis-Menten kinetics over a wide range of oxygen concentrations in the absence of electron donor. Kinetics analysis, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DeWitt, D.L.; Smith, W.L.
Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence [published erratum appears in Proc Natl Acad Sci U S A 1988 Jul;85(14):5056]
Proc. Natl. Acad. Sci. USA
85
1412-1416
1988
Ovis aries
brenda
Saeed, S.A.; Butt, N.M.; McDonald-Gibson, W.J.
The effect of ellagic acid and tannic acid on prostaglandin synthase activity in bovine seminal-vesicle homogenates
Biochem. Soc. Trans.
8
443
1981
Bos taurus
-
brenda
Narayanan, R.; Harrington, M.G.
Hydroperoxyeicosatetraenoic acid: an activator of prostaglandin synthase activity
Biochem. Soc. Trans.
8
449-450
1980
Ovis aries
brenda
Denning-Kendall, P.A.; Saeed, S.A.
Effect of cofactor, enzyme and substrate concentration on inhibition of prostaglandin synthase of bull seminal vesicles by human serum, haptoglobin and albumin
Biochem. Soc. Trans.
9
379-380
1981
Bos taurus
-
brenda
Ryan, J.; Davis, G.
Inhibition of prostaglandin synthase by some low molecular mass fatty acids
Biochem. Soc. Trans.
16
398-399
1988
Rattus norvegicus
-
brenda
Hemler, M.; Lands, W.E.M.
Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme
J. Biol. Chem.
251
5575-5579
1976
Ovis aries
brenda
Miyamoto, T.; Ogino, N.; Yamamoto, S.; Hayaishi, O.
Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
J. Biol. Chem.
251
2629-2636
1976
Bos taurus
brenda
Marnett, L.J.; Dix, T.A.; Sachs, R.J.; Siedlik, P.H.
Oxidations by fatty acid hydroperoxides and prostaglandin synthase
Adv. Prostaglandin Thromboxane Leukot. Res.
11
79-86
1983
Ovis aries
brenda
Zenser, T.V.; Mattammal, M.B.; Armbrecht, H.J.; Davis, B.B.
Benzidine binding to nucleic acids mediated by the peroxidative activity of prostaglandin endoperoxide synthetase
Cancer Res.
40
2839-2845
1980
Oryctolagus cuniculus
brenda
Egan, R.W.; Gale, P.O.H.; Baptista, E.M.; Kennicott, K.L.; VandenHeuvel, W.J.A.; Walker, R.W.; Fagerness, P.W.; Kuehl, F.A.
Oxidation reactions by prostaglandin cyclooxygenase-hydroperoxidase
J. Biol. Chem.
256
7352-7361
1981
Ovis aries
brenda
Van der Ouderaa, F.J.; Buytenhek, M.; Nugteren, D.H.; Van Dorp, D.A.
Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid
Eur. J. Biochem.
109
1-8
1980
Ovis aries
brenda
Mizuno, K.; Yamamoto, S.; Lands, W.E.M.
Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities
Prostaglandins
23
743-757
1982
Bos taurus
brenda
DeWitt, D.L.; Rollins, T.E.; Day, J.S.; Gauger, J.A.; Smith, W.L.
Orientation of the active site and antigenic determinants of prostaglandin endoperoxide synthase in the endoplasmic reticulum
J. Biol. Chem.
256
10375-10382
1981
Ovis aries
brenda
Smith, W.L.
Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells
Annu. Rev. Physiol.
48
251-262
1986
Bos taurus, Homo sapiens, Sus scrofa
brenda
Roth, G.J.; Siok, C.J.; Ozols, J.
Structural characteristics of prostaglandin synthetase from sheep vesicular gland
J. Biol. Chem.
255
1301-1304
1980
Ovis aries
brenda
Marnett, L.J.; Chen, Y.N.P.; Maddipati, K.R.; Ple, P.; Labeque, R.
Functional differentiation of cyclooxygenase and peroxidase activities of prostaglandin synthase by trypsin treatment. Possible location of a prosthetic heme binding site
J. Biol. Chem.
263
16532-16535
1988
Ovis aries
brenda
Marnett, L.J.; Siedlick, P.H.; Ochs, R.C.; Pagels, W.R.; Das, M.; Honn, K.V.; Warnock, R.H.; Tainer, B.E.; Eling, T.E.
Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom
Mol. Pharmacol.
26
328-335
1984
Ovis aries
brenda
Ohki, S.; Ogino, N.; Yamamoto, S.; Hayaishi, O.; Yamamoto, H.; Miyake, H.; Hayashi, M.
Inhibition of prostaglandin endoperoxide synthetase by thiol analogues of prostaglandin
Proc. Natl. Acad. Sci. USA
74
144-148
1977
Bos taurus
brenda
Wlodawer, P.; Samuelsson, B.
On the organization and mechanism of prostaglandin synthetase
J. Biol. Chem.
248
5673-5678
1973
Ovis aries
brenda
Golly, I.; Hlavica, P.
N-Oxidation of 4-chloroaniline by prostaglandin synthase
Biochem. J.
260
803-809
1985
Ovis aries
brenda
Tai, H.H.; Tai, C.L.; Hollander, C.S.
Biosynthesis of prostaglandins in rabbit kidney medulla. Properties of prostaglandin synthase
Biochem. J.
154
257-264
1976
Oryctolagus cuniculus
brenda
Friedman, Y.; Lang, M.; Burke, G.
Further characterization of bovine thyroid prostaglandin synthase
Biochim. Biophys. Acta
397
331-341
1975
Bos taurus
brenda
Parkes, D.G.; Eling, T.E.
Characterization of prostaglandin synthetase in guinea pig lung. Isolation of a new prostaglandin derivative from arachidonic acid
Biochemistry
13
2598-2604
1974
Cavia porcellus
brenda
Pace-Asciak, C.
Prostaglandin synthetase activity in the rat stomach fundus. Activation by L-norepinephrine and related compounds
Biochim. Biophys. Acta
280
161-171
1972
Rattus norvegicus
brenda
Miller, D.B.; Munster, D.; Wasvary, J.S.; Simke, J.P.; Peppard, J.V.; Bowen, B.R.; Marshall, P.J.
The heterologous expression and characterization of human prostaglandin G/H synthase-2 (COX-2)
Biochem. Biophys. Res. Commun.
201
356-362
1994
Homo sapiens
brenda
Liu, J.; Antaya, M.; Goff, A.K.; Boerboom, D.; Silversides, D.W.; Lussier, J.G.; Sirois, J.
Molecular characterization of bovine prostaglandin G/H synthase-2 and regulation in uterine stromal cells
Biol. Reprod.
64
983-991
2001
Bos taurus (O62698), Bos taurus
brenda
Doualla-Bell, F.; Guay, J.M.; Bourgoin, S.; Fortier, M.A.
Prostaglandin G/H synthase (PGHS)-2 expression in bovine myometrium: influence of steroid hormones and PGHS inhibitors
Biol. Reprod.
59
1433-1438
1998
Bos taurus
brenda
Kargman, S.; Wong, E.; Greig, G.M.; Falgueyret, J.P.; Cromlish, W.; Ethier, D.; Yergey, J.A.; Riendeau, D.; Evans, J.F.; Kennedy, B.; Tagari, P.; Francis, D.A.; O'Neill, G.P.
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
Biochem. Pharmacol.
52
1113-1125
1996
Homo sapiens
brenda
Forghani, F.; Ouellet, M.; Keen, S.; Percival, M.D.; Tagari, P.
Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence
Anal. Biochem.
264
216-221
1998
Homo sapiens
brenda
Mancini, J.A.; Vickers, P.J.; O'Neill, G.P.; Boily, C.; Falgueyret, J.P.; Riendeau, D.
Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs
Mol. Pharmacol.
51
52-60
1997
Homo sapiens
brenda
George, H.J.; Van Dyk, D.E.; Straney, R.A.; Trzaskos, J.M.; Copeland, R.A.
Expression purification and characterization of recombinant human inducible prostaglandin G/H synthase from baculovirus-infected insect cells
Protein Expr. Purif.
7
19-26
1996
Homo sapiens
brenda
Smith, C.J.; Marnett, L.J.
Effects of cysteine-to-serine mutations on structural and functional properties of prostaglandin endoperoxide synthase
Arch. Biochem. Biophys.
335
342-350
1996
Ovis aries
brenda
Ishii, R.; Horie, M.; Saito, K.; Arisawa, M.; Kitanaka, S.
Prostaglandin E(2) production and induction of prostaglandin endoperoxide synthase-2 is inhibited in a murine macrophage-like cell line, RAW 264.7, by Mallotus japonicus phloroglucinol derivatives
Biochim. Biophys. Acta
1571
115-123
2002
Mus musculus
brenda
Barnett, J.; Chow, J.; Ives, D.; Chiou, M.; Mackenzie, R.; Osen, E.; Nguyen, B.; Tsing, S.; Bach, C.; Freire, J.; et al.
Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system
Biochim. Biophys. Acta
1209
130-139
1994
Homo sapiens
brenda
Kargman, S.; Charleson, S.; Cartwright, M.; Frank, J.; Riendeau, D.; Mancini, J.; Evans, J.; O'Neill, G.
Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
Gastroenterology
111
445-454
1996
Canis lupus familiaris, Homo sapiens, Macaca mulatta, Rattus norvegicus, Saimiri sciureus
brenda
Boutemmine, D.; Bouchard, N.; Boerboom, D.; Jones, H.E.; Goff, A.K.; Dore, M.; Sirois, J.
Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro
Endocrinology
143
1134-1143
2002
Canis lupus familiaris
brenda
Patrignani, P.; Panara, M.R.; Sciulli, M.G.; Santini, G.; Renda, G.; Patrono, C.
Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
J. Physiol. Pharmacol.
48
623-631
1997
Homo sapiens
brenda
Chulada, P.C.; Loftin, C.D.; Winn, V.D.; Young, D.A.; Tiano, H.F.; Eling, T.E.; Langenbach, R.
Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid
Arch. Biochem. Biophys.
330
301-313
1996
Mus musculus
brenda
Mancini, J.A.; Riendeau, D.; Falgueyret, J.P.; Vickers, P.J.; O'Neill, G.P.
Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety
J. Biol. Chem.
270
29372-29377
1995
Ovis aries
brenda
Meade, E.A.; Smith, W.L.; DeWitt, D.L.
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
J. Biol. Chem.
268
6610-6614
1993
Mus musculus
brenda
O'Neill, G.P.; Mancini, J.A.; Kargman, S.; Yergey, J.; Kwan, M.Y.; Falgueyret, J.P.; Abramovitz, M.; Kennedy, B.P.; Ouellet, M.; Cromlish, W.
Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid
Mol. Pharmacol.
45
245-254
1994
Homo sapiens
brenda
Roberts, S.B.; Langenau, D.M.; Goetz, F.W.
Cloning and characterization of prostaglandin endoperoxide synthase-1 and -2 from the brook trout ovary
Mol. Cell. Endocrinol.
160
89-97
2000
Salvelinus fontinalis
brenda
Rogge, C.E.; Liu, W.; Wu, G.; Wang, L.H.; Kulmacz, R.J.; Tsai, A.L.
Identification of Tyr504 as an alternative tyrosyl radical site in human prostaglandin H synthase-2
Biochemistry
43
1560-1568
2004
Homo sapiens
brenda
Narayansingh, R.M.; Senchyna, M.; Vijayan, M.M.; Carlson, J.C.
Expression of prostaglandin G/H synthase (PGHS) and heat shock protein-70 (HSP-70) in the corpus luteum (CL) of prostaglandin F2 alpha-treated immature superovulated rats
Can. J. Physiol. Pharmacol.
82
363-371
2004
Rattus norvegicus
brenda
Bambai, B.; Rogge, C.E.; Stec, B.; Kulmacz, R.J.
Role of Asn-382 and Thr-383 in activation and inactivation of human prostaglandin H synthase cyclooxygenase catalysis
J. Biol. Chem.
279
4084-4092
2004
Homo sapiens
brenda
Sayasith, K.; Bouchard, N.; Sawadogo, M.; Lussier, J.G.; Sirois, J.
Molecular characterization and role of bovine upstream stimulatory factor 1 and 2 in the regulation of the prostaglandin G/H synthase-2 promoter in granulosa cells
J. Biol. Chem.
279
6327-6336
2004
Bos taurus
brenda
Gupta, K.; Selinsky, B.S.; Kaub, C.J.; Katz, A.K.; Loll, P.J.
The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase
J. Mol. Biol.
335
503-518
2003
Ovis aries
brenda
Snipes, J.A.; Kis, B.; Shelness, G.S.; Hewett, J.A.; Busija, D.W.
Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat
J. Pharmacol. Exp. Ther.
313
668-676
2005
Rattus norvegicus (Q63921)
brenda
Giannoulias, D.; Haluska, G.J.; Gravett, M.G.; Sadowsky, D.W.; Challis, J.R.; Novy, M.J.
Localization of prostaglandin H synthase, prostaglandin dehydrogenase, corticotropin releasing hormone and glucocorticoid receptor in rhesus monkey fetal membranes with labor and in the presence of infection
Placenta
26
289-297
2005
Macaca mulatta
brenda
Gupta, K.; Selinsky, B.S.; Loll, P.J.
2.0 A structure of prostaglandin H2 synthase-1 reconstituted with a manganese porphyrin cofactor
Acta crystallogr. Sect. D
62
151-156
2006
Ovis aries
brenda
Rogge, C.E.; Ho, B.; Liu, W.; Kulmacz, R.J.; Tsai, A.L.
Role of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2
Biochemistry
45
523-532
2006
Homo sapiens
brenda
Chubb, A.J.; Fitzgerald, D.J.; Nolan, K.B.; Moman, E.
The productive conformation of prostaglandin G2 at the peroxidase site of prostaglandin endoperoxide H synthase: docking, molecular dynamics, and site-directed mutagenesis studies
Biochemistry
45
811-820
2006
Homo sapiens
brenda
Tsaplina, L.A.; Karatasso, Y.O.; Filimonov, I.S.; Vrzheshch, P.V.
Kinetic mechanism of the bifunctional enzyme prostaglandin-H-synthase. Effect of electron donors on the cyclooxygenase reaction
Biochemistry (Moscow)
71
1247-1255
2006
Ovis aries (P05979), Ovis aries (P79208)
brenda
Winnall, W.R.; Ali, U.; Obryan, M.K.; Hirst, J.J.; Whiley, P.A.; Muir, J.A.; Hedger, M.P.
Constitutive expression of prostaglandin-endoperoxide synthase 2 by somatic and spermatogenic cells is responsible for prostaglandin E2 production in the adult rat testis
Biol. Reprod.
76
759-768
2007
Rattus norvegicus
brenda
Zhang, D.; Wood, C.E.
Neuronal prostaglandin endoperoxide synthase 2 responses to oxygen and glucose deprivation are mediated by mitogen-activated protein kinase ERK1/2
Brain Res.
1060
100-107
2005
Homo sapiens (P35354)
brenda
Censarek, P.; Freidel, K.; Hohlfeld, T.; Schroer, K.; Weber, A.A.
Human cyclooxygenase-1b is not the elusive target of acetaminophen
Eur. J. Pharmacol.
551
50-53
2006
Homo sapiens
brenda
Liu, W.; Cao, D.; Oh, S.F.; Serhan, C.N.; Kulmacz, R.J.
Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases
FASEB J.
20
1097-1108
2006
Ovis aries, Homo sapiens (P23219), Homo sapiens (P35354), Salvelinus fontinalis (Q9PTN3), Salvelinus fontinalis (Q9PW89), Salvelinus fontinalis
brenda
Jeng, W.; Ramkissoon, A.; Parman, T.; Wells, P.G.
Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration
FASEB J.
20
638-650
2006
Mus musculus
brenda
Cabrera, R.A.; Dozier, B.L.; Duffy, D.M.
Prostaglandin-endoperoxide synthase (PTGS1 and PTGS2) expression and prostaglandin production by normal monkey ovarian surface epithelium
Fertil. Steril.
86 Suppl 4
1088-1096
2006
Macaca fascicularis
brenda
Trostchansky, A.; Odonnell, V.B.; Goodwin, D.C.; Landino, L.M.; Marnett, L.J.; Radi, R.; Rubbo, H.
Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: A free radical mechanism of inactivation
Free Radic. Biol. Med.
42
1029-1038
2007
Ovis aries
brenda
MirAfzali, Z.; Leipprandt, J.R.; McCracken, J.L.; DeWitt, D.L.
Topography of the prostaglandin endoperoxide H2 synthase-2 in membranes
J. Biol. Chem.
281
28354-28364
2006
Homo sapiens
brenda
Deeb, R.S.; Hao, G.; Gross, S.S.; Laine, M.; Qiu, J.H.; Resnick, B.; Barbar, E.J.; Hajjar, D.P.; Upmacis, R.K.
Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite
J. Lipid Res.
47
898-911
2006
Ovis aries
brenda
Reininger, E.A.; Bauer, R.
Prostaglandin-H-synthase (PGHS)-1 and -2 microtiter assays for the testing of herbal drugs and in vitro inhibition of PGHS-isoenzyms by polyunsaturated fatty acids from Platycodi radix
Phytomedicine
13
164-169
2006
Ovis aries (P05979), Ovis aries (P79208)
brenda
Sheldrick, E.L.; Derecka, K.; Marshall, E.; Chin, E.C.; Hodges, L.; Wathes, D.C.; Abayasekara, D.R.; Flint, A.P.
Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus
Biochem. J.
406
175-183
2007
Bos taurus (O62698), Bos taurus
brenda
Gersting, J.; Schaub, C.E.; Keller-Wood, M.; Wood, C.E.
Inhibition of brain prostaglandin endoperoxide synthase-2 prevents the preparturient increase in fetal adrenocorticotropin secretion in the sheep fetus
Endocrinology
149
4128-4136
2008
Ovis aries (P05979), Ovis aries (P79208), Ovis aries
brenda
Tsai, A.L.; Kulmacz, R.J.
Prostaglandin H synthase: Resolved and unresolved mechanistic issues
Arch. Biochem. Biophys.
493
103-124
2010
Ovis aries (P05979), Homo sapiens (P23219), Homo sapiens (P35354)
brenda
Goncalves, L.L.; Ramkissoon, A.; Wells, P.G.
Prostaglandin H synthase-1-catalyzed bioactivation of neurotransmitters, their precursors, and metabolites: oxidative DNA damage and electron spin resonance spectroscopy studies
Chem. Res. Toxicol.
22
842-852
2009
Ovis aries (P05979)
brenda
Seo, H.; Kim, M.; Choi, Y.; Lee, C.K.; Ka, H.
Analysis of lysophosphatidic acid (LPA) receptor and LPA-induced endometrial prostaglandin-endoperoxide synthase 2 expression in the porcine uterus
Endocrinology
149
6166-6175
2008
Sus scrofa
brenda
Liu, J.; Park, E.S.; Jo, M.
Runt-related transcription factor 1 regulates luteinized hormone-induced prostaglandin-endoperoxide synthase 2 expression in rat periovulatory granulosa cells
Endocrinology
150
3291-3300
2009
Rattus norvegicus
brenda
Enami, Y.; Bandi, S.; Kapoor, S.; Krohn, N.; Joseph, B.; Gupta, S.
Hepatic stellate cells promote hepatocyte engraftment in rat liver after prostaglandin-endoperoxide synthase inhibition
Gastroenterology
136
2356-2364
2009
Rattus norvegicus (P35355), Rattus norvegicus (Q63921)
brenda
Gersting, J.A.; Schaub, C.E.; Wood, C.E.
Development of prostaglandin endoperoxide synthase expression in the ovine fetal central nervous system and pituitary
Gene Expr. Patterns
9
603-611
2009
Ovis aries (P05979), Ovis aries (P79208), Ovis aries
brenda
Ilyina, A.; Huerta-Guel, P.; Martinez-Hernandez, J.; Rodriguez-Martinez, J.; Gorokhovsky, A.
Stability and activity of bovine prostaglandin H synthase immobilized on Opuntia imbricata (coyonoxtle)
J. Mol. Catal. B
51
1-9
2008
Bos taurus
-
brenda
Kawakami, Y.; Nakamura, T.; Hosokawa, T.; Suzuki-Yamamoto, T.; Yamashita, H.; Kimoto, M.; Tsuji, H.; Yoshida, H.; Hada, T.; Takahashi, Y.
Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms
Prostaglandins Leukot. Essent. Fatty Acids
80
239-245
2009
Ovis aries (P05979), Ovis aries (P79208), Homo sapiens (P23219), Homo sapiens (P35354), Homo sapiens
brenda
Gillio-Meina, C.; Phang, S.H.; Mather, J.P.; Knight, B.S.; Kennedy, T.G.
Expression patterns and role of prostaglandin-endoperoxide synthases, prostaglandin E synthases, prostacyclin synthase, prostacyclin receptor, peroxisome proliferator-activated receptor delta and retinoid x receptor alpha in rat endometrium during artificially-induced decidualization
Reproduction
137
537-552
2009
Rattus norvegicus (P35355), Rattus norvegicus (Q63921)
brenda
Bedi, G.; Tonzibo, Z.; Oussou, K.; Choppard, C.; Mahy, J.; NGuessan, T.
Effect of essential oil of chromoleana odorata (asteraceae) from ivory coast, on cyclooxygenase function of prostagladin-H synthase activity
Afr. J. Pharm. Pharmacol.
4
535-538
2010
Ovis aries
-
brenda
Trushkin, N.A.; Filimonov, I.S.; Vrzheshch, P.V.
Inhibition of cyclooxygenase activity of prostaglandin-H-synthase by excess substrate (molecular oxygen)
Biochemistry (Moscow)
75
1368-1373
2010
Ovis aries
brenda
Lee, C.J.; Goncalves, L.L.; Wells, P.G.
Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism
FASEB J.
25
2468-2483
2011
Oryctolagus cuniculus
brenda
Ramkissoon, A.; Wells, P.G.
Human prostaglandin H synthase (hPHS)-1- and hPHS-2-dependent bioactivation, oxidative macromolecular damage, and cytotoxicity of dopamine, its precursor, and its metabolites
Free Radic. Biol. Med.
50
295-304
2011
Homo sapiens
brenda
Vecchio, A.J.; Simmons, D.M.; Malkowski, M.G.
Structural basis of fatty acid substrate binding to cyclooxygenase-2
J. Biol. Chem.
285
22152-22163
2010
Mus musculus (Q05769), Mus musculus
brenda
Liu, W.; Poole, E.M.; Ulrich, C.M.; Kulmacz, R.J.
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors
Pharmacogenomics J.
11
337-347
2010
Homo sapiens
brenda
Ramkissoon, A.; Wells, P.G.
Human prostaglandin H synthase (hPHS)-1 and hPHS-2 in amphetamine analog bioactivation, DNA oxidation, and cytotoxicity
Toxicol. Sci.
120
154-162
2011
Homo sapiens
brenda
Varvas, K.; Kasvandik, S.; Hansen, K.; Jaerving, I.; Morell, I.; Samel, N.
Structural and catalytic insights into the algal prostaglandin H synthase reveal atypical features of the first non-animal cyclooxygenase
Biochim. Biophys. Acta
1831
863-871
2013
Agarophyton vermiculophyllum (I6VVK9), Agarophyton vermiculophyllum, Coccotylus truncatus (I6VCP8), Coccotylus truncatus
brenda
Joseph, T.; Zalenskaya, I.A.; Sawyer, L.C.; Chandra, N.; Doncel, G.F.
Seminal plasma induces prostaglandin-endoperoxide synthase (PTGS) 2 expression in immortalized human vaginal cells: involvement of semen prostaglandin E2 in PTGS2 upregulation
Biol. Reprod.
88
13
2013
Homo sapiens (P35354), Homo sapiens
brenda
Tsikas, D.; Suchy, M.T.; Niemann, J.; Tossios, P.; Schneider, Y.; Rothmann, S.; Gutzki, F.M.; Froelich, J.C.; Stichtenoth, D.O.
Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2?
FEBS Lett.
586
3723-3730
2012
Homo sapiens (P23219), Homo sapiens (P35354)
brenda
Zerani, M.; Catone, G.; Betti, G.; Parillo, F.
Immunopresence and functional activity of prostaglandin-endoperoxide synthases and nitric oxide synthases in bovine corpora lutea during diestrus
Folia Morphol. (Praha)
72
36-40
2013
Bos taurus (O62664), Bos taurus (O62698), Bos taurus
brenda
Trostchansky, A.; Bonilla, L.; Thomas, C.P.; ODonnell, V.B.; Marnett, L.J.; Radi, R.; Rubbo, H.
Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2
J. Biol. Chem.
286
12891-12900
2011
Homo sapiens (P23219), Homo sapiens (P35354), Homo sapiens
brenda
Brant, K.A.; Leikauf, G.D.
Dysregulation of FURIN by prostaglandin-endoperoxide synthase 2 in lung epithelial NCI-H292 cells
Mol. Carcinog.
53
192-200
2012
Homo sapiens (P35354)
brenda
Kukk, K.; Jaerving, R.; Samel, N.
Purification and characterization of the recombinant human prostaglandin H synthase-2 expressed in Pichia pastoris
Protein Expr. Purif.
83
182-189
2012
Homo sapiens (P23219), Homo sapiens (P35354), Homo sapiens
brenda
Gupta, K.; Selinsky, B.S.
Bacterial and algal orthologs of prostaglandin H2 synthase novel insights into the evolution of an integral membrane protein
Biochim. Biophys. Acta
1848
83-94
2015
Ovis aries (P05979)
brenda
Piranda, D.; Abreu, R.; Freitas-Alves, D.; de Carvalho, M.; Vianna-Jorge, R.
Modulation of the prostaglandin-endoperoxide synthase 2 gene expression by variant haplotypes Influence of the 3'-untranslated region
Braz. J. Med. Biol. Res.
51
e6546
2018
Homo sapiens
brenda
Das, A.; Gogoi, U.; Kalita, J.; Sandilya, S.
Molecular docking study of a series of substituted xanthone derivatives as novel COX-2 inhibitors targeting prostaglandin endoperoxide synthase-2
Curr. Enzyme Inhib.
12
195-204
2016
Mus musculus (Q05769)
-
brenda
Herington, J.L.; OBrien, C.; Robuck, M.F.; Lei, W.; Brown, N.; Slaughter, J.C.; Paria, B.C.; Mahadevan-Jansen, A.; Reese, J.
Prostaglandin-endoperoxide synthase 1 mediates the timing of parturition in mice despite unhindered uterine contractility
Endocrinology
159
490-505
2017
Mus musculus
brenda
Li, N.; Wang, Q.; Zhu, T.; Qiao, L.; Zhang, F.; Mi, R.; Wang, B.; Chen, L.; Gu, J.; Lu, Y.; Zheng, Q.
In vitro functional characterization of prostaglandin-endoperoxide synthase 2 during chondrocyte hypertrophic differentiation
Oncotarget
7
36280-36292
2016
Mus musculus
brenda
Rebordao, M.R.; Galvao, A.; Pinto-Bravo, P.; Pinheiro, J.; Gamboa, S.; Silva, E.; Mateus, L.; Ferreira-Dias, G.
Endometrial prostaglandin synthases, ovarian steroids, and oxytocin receptors in mares with oxytocin-induced luteal maintenance
Theriogenology
87
193-204
2017
Equus caballus
brenda
El-Nagar, M.K.S.; Abdu-Allah, H.H.M.; Salem, O.I.A.; Kafafy, A.N.; Farghaly, H.S.M.
Novel N-substituted 5-aminosalicylamides as dual inhibitors of cyclooxygenase and 5-lipoxygenase enzymes Synthesis, biological evaluation and docking study
Bioorg. Chem.
78
80-93
2018
Homo sapiens, Ovis aries
brenda
Park, N.Y.; Im, S.; Jiang, Q.
Different forms of vitamin E and metabolite 13-carboxychromanols inhibit cyclooxygenase-1 and its catalyzed thromboxane in platelets, and tocotrienols and 13-carboxychromanols are competitive inhibitors of 5-lipoxygenase
J. Nutr. Biochem.
100
108884
2022
Homo sapiens
brenda